ADRB3 Signaling Pathway in Human Adipose Tissue

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions

Obesity, Prediabetes

Interventions

DRUG

Mirabegron

Single dose, 100mg oral mirabegron

Trial Locations (1)

UC San Diego Altman Clinical & Translational Research Institute, La Jolla

All Listed Sponsors

lead

University of California, San Diego

OTHER

NCT05634174 - ADRB3 Signaling Pathway in Human Adipose Tissue | Biotech Hunter | Biotech Hunter